SE (NASDAQ:ARGX) said on Friday that it has received approval from the European Commission for its IgG Fc-antibody fragment, ...

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

Creative Biolabs recently rolled out a three-dimensional upgrade designed to make antibodies safer, more potent, and easier to develop. SHIRLEY, NY, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- ...

The Inducement Grant has a ten-year term and an exercise price per share of $9.97, which is equal to the closing price of Zenas’ common stock on the Grant Date. The Inducement Grant will vest over a ...

近日，复旦大学生命科学学院黄强课题组与复宏汉霖技术运营团队合作，于 Advanced Science 发表题为“ Enhancing the Protein Stability of an Anticancer VHH-Fc Heavy Chain Antibody through Computational Modeling and Variant Design ” 的论文 ...

Incyte INCY announced that the FDA has approved its humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, ...

Treated recipients received either 3 mg/kg rapamycin intraperitoneally for the first 14 d after transplantation (days 0-13) and/or 0.25 mg/dose CD40L-specific antibody (days 0, 2, 4, 7 and 10 ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

在肿瘤治疗中，相比于化疗药物，近年来生物制药日新月异，尤其是以单克隆抗体为代表的创新药已广泛应用于临床，比如大家耳熟能详的贝伐珠单抗，曲妥珠单抗，帕博利珠单抗等。由于大部分临床医生，不熟悉免疫基础知识，在学术交流中，单克隆抗体抗癌机制部分，令人费解的 ...